.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, patients along with metastatic gastrointestinal growths that acquired biomarker-matched treatments based upon flowing growth DNA profiling presented a better professional perk than those getting incomparable therapy.